keyword
MENU ▼
Read by QxMD icon Read
search

Asenapine

keyword
https://www.readbyqxmd.com/read/29758999/movement-disorders-associated-with-antipsychotic-medication-in-people-with-schizophrenia-an-overview-of-cochrane-reviews-and-meta-analysis
#1
Davide Martino, Vikram Karnik, Sydney Osland, Thomas R E Barnes, Tamara M Pringsheim
Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted meta-analyses of randomised controlled trials included in the Cochrane Database of Systematic Reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with SGAs (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, L-sulpiride, and ziprasidone) approved in Canada and the UK, comparing them with haloperidol and chlorpromazine...
January 1, 2018: Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie
https://www.readbyqxmd.com/read/29730876/qtc-prolongation-and-ventricular-trigemini-with-asenapine-a-case-report
#2
Jesjeet Singh Gıll, Ahmad Hatim Sulaıman
Asenapine is one of the newer atypical antipsychotics on the market. It is a sublingually administered drug that is indicated for the treatment of both schizophrenia and bipolar disorder, and is considered to be safe and well tolerated. Herein, we report a 71-year-old female with a history of bipolar disorder who had ventricular trigemini and experienced a large increase in her QTc interval after starting treatment with asenapine. These changes ceased following withdrawal of asenapine. In this case report, we discuss the importance of cardiac monitoring when switching antipsychotics, even to those that are considered to have low cardiac risk...
2018: Türk Psikiyatri Dergisi, Turkish Journal of Psychiatry
https://www.readbyqxmd.com/read/29715183/c-fos-expression-in-the-hypothalamic-paraventricular-nucleus-after-a-single-treatment-with-a-typical-haloperidol-and-nine-atypical-antipsychotics-a-pilot-study
#3
Alexander Kiss
OBJECTIVE: The aim of the present study was to find out whether acute effect of different doses of selected antipsychotics including aripiprazole (ARI), amisulpride (AMI), asenapine (ASE), haloperidol (HAL), clozapine (CLO), risperidone (RIS), quetiapine (QUE), olanzapine (OLA), ziprasidone (ZIP), and paliperidone (PAL) may have a stimulatory impact on the c-Fos expression in the hypothalamic paraventricular nucleus (PVN) neurons. METHODS: Adult male Wistar rats weighing 280-300 g were used...
April 1, 2018: Endocrine Regulations
https://www.readbyqxmd.com/read/29694244/cost-effectiveness-of-long-acting-injectable-aripiprazole-once-monthly-400-mg-in-bipolar-i-disorder-in-the-usa
#4
Margarida Augusto, Mallik Greene, Maëlys Touya, Samantha Min Sweeney, Heidi Waters
AIM: To evaluate the cost-effectiveness of aripiprazole once-monthly 400/300 mg (AOM 400) in maintenance monotherapy treatment of bipolar I disorder (BP-I). METHODS: A de novo lifetime Markov model was developed for BP-I using available data for AOM 400 and relevant comparators. Base-case analysis considered costs and outcomes from the US payer perspective. RESULTS: The cost per quality-adjusted life year gained with AOM 400 versus comparators ranged from US$2007 versus oral asenapine to dominance (i...
April 25, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29694243/budget-impact-analysis-of-long-acting-injectable-aripiprazole-once-monthly-400-mg-in-bipolar-i-disorder-in-the-usa
#5
Margarida Augusto, Mallik Greene, Maëlys Touya, Samantha Min Sweeney, Heidi Waters
AIM: To estimate the budget impact (BI) of introducing aripiprazole once-monthly 400 mg/300 mg (AOM 400) in the maintenance monotherapy treatment of bipolar I disorder versus long-acting injectables, oral antipsychotics and best supportive care. METHODS: A BI model was developed from a US-payer perspective using treatment-related, hospitalization and adverse event management cost estimates for a hypothetical 1,000,000-member health plan over a 5-year period. RESULTS: Market share of AOM 400 was predicted to increase from 0...
April 25, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29536616/canadian-network-for-mood-and-anxiety-treatments-canmat-and-international-society-for-bipolar-disorders-isbd-2018-guidelines-for-the-management-of-patients-with-bipolar-disorder
#6
Lakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, Ayal Schaffer, David J Bond, Benicio N Frey, Verinder Sharma, Benjamin I Goldstein, Soham Rej, Serge Beaulieu, Martin Alda, Glenda MacQueen, Roumen V Milev, Arun Ravindran, Claire O'Donovan, Diane McIntosh, Raymond W Lam, Gustavo Vazquez, Flavio Kapczinski, Roger S McIntyre, Jan Kozicky, Shigenobu Kanba, Beny Lafer, Trisha Suppes, Joseph R Calabrese, Eduard Vieta, Gin Malhi, Robert M Post, Michael Berk
The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments...
March 2018: Bipolar Disorders
https://www.readbyqxmd.com/read/29361326/evidence-based-review-of-pharmacotherapy-for-acute-agitation-part-1-onset-of-efficacy
#7
Leslie S Zun
BACKGROUND: The main goal of antipsychotic medication in the management of acute agitation in the emergency department is to rapidly induce calm without oversedation, enabling patients to participate in their own care. However, there is a paucity of comparative studies, particularly with newer fast-acting second-generation antipsychotic agents. OBJECTIVE OF THE REVIEW: This structured evidence-based review compared the onset of efficacy of antipsychotic treatments for acute agitation using data from randomized controlled trials identified by a literature search of the PubMed database...
March 2018: Journal of Emergency Medicine
https://www.readbyqxmd.com/read/29237385/systemic-administrations-of-antipsychotic-asenapine-pre-or-postnatal-does-not-induce-anxiety-like-behaviors-in-mice
#8
Maria Silvia Oliveira, Thais Souza Barbosa de Souza, Daniela Miranda Farias, Rozimeri Fatima Coletti, Jorge Aparecido de Barros, Carolina Gomes Carrilho, Susana Elisa Moreno, Eric Murillo Murillo Rodriguez, Sergio Machado, Andre Barciela Veras
Asenapine is an atypical antipsychotic approved by US Food and Drug Administration in 2009 and by European Medicines Agency in 2010 for schizophrenia and bipolar disorder treatment. Currently, many studies have been developed in an attempt to clarify and minimize the risks related to the use of psychotropic during pre/postnatal period on patients with a history of mental disorders. To this finality, the purpose of the following work was to test on animal models the impact of being exposed to this medication during perinatal period upon anxiety and exploration/emotionality of female mice's descendants submitting them, in adulthood, to the Open Field and Elevated Plus Maze test...
December 13, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/29219316/from-the-promiscuous-asenapine-to-potent-fluorescent-ligands-acting-at-a-series-of-aminergic-g-protein-coupled-receptors
#9
Candide Hounsou, Corinne Baehr, Vincent Gasparik, Doria Alili, Abderazak Belhocine, Thiéric Rodriguez, Elodie Dupuis, Thomas Roux, André Mann, Denis Heissler, Jean-Philippe Pin, Thierry Durroux, Dominique Bonnet, Marcel Hibert
Monoamine neurotransmitters such as serotonin, dopamine, histamine, and noradrenaline have important and varied physiological functions and similar chemical structures. Representing important pharmaceutical drug targets, the corresponding G-protein-coupled receptors (termed aminergic GPCRs) belong to the class of cell membrane receptors and share many levels of similarity as well. Given their pharmacological and structural closeness, one could hypothesize the possibility to derivatize a ubiquitous ligand to afford rapidly fluorescent probes for a large set of GPCRs to be used for instance in FRET-based binding assays...
January 11, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29200857/reversal-of-olanzapine-induced-weight-gain-in-a-patient-with-schizophrenia-by-switching-to-asenapine-a-case-report
#10
Kosuke Okazaki, Kazuhiko Yamamuro, Toshifumi Kishimoto
Aims: Antipsychotics are effective for treating schizophrenia, but atypical antipsychotics can cause several adverse side effects including weight gain, hyperprolactinemia, and extrapyramidal symptoms. Moreover, weight gain increases the risk of metabolic diseases. Methods: We treated a case of olanzapine-induced weight gain in a 41-year-old man with schizophrenia by switching his medication from olanzapine to asenapine. Results: The weight gain improved after switching the medication, from 80...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29191711/analyzing-test-batteries-in-animal-models-of-psychopathology-with-multivariate-analysis-of-variance-manova-one-possible-approach-to-increase-external-validity
#11
Yelena Stukalin, Haim Einat
BACKGROUND: One concern regarding animal models of psychopathology is unclear external validity. One way to establish external validity is to examine measures representing separate facets of the pathology with a battery of tests in the same cohort of animals. Additionally, utilizing the same animals in a battery of tests can help to reduce the number of animals in research. However, issues had been raised regarding the analysis of data coming from batteries and the standard practice is to analyze each test separately...
November 28, 2017: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/29189421/asenapine-in-the-management-of-impulsivity-and-aggressiveness-in-bipolar-disorder-and-comorbid-borderline-personality-disorder-an-open-label-uncontrolled-study
#12
Andrea Aguglia, Ludovico Mineo, Alessandro Rodolico, Maria S Signorelli, Eugenio Aguglia
Borderline personality disorder (BPD) often co-occurres with bipolar disorder (BD). Impulsivity and aggressiveness represent core shared features and their pharmacological management is mainly based on mood stabilizers and antipsychotics, although scarce evidence is available for this context of comorbidity. The aim of the present study was to evaluate the role of Asenapine as an adjunctive drug for reducing aggressiveness and impulsivity in a sample of Italian BD type I outpatients with or without a comorbid BPD...
November 17, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29170943/asenapine-treatment-in-pediatric-patients-with-bipolar-i-disorder-or-schizophrenia-a-review
#13
REVIEW
Ekaterina Stepanova, Bradley Grant, Robert L Findling
Asenapine, administered as a twice-daily (BID) sublingual tablet, is approved in the US as monotherapy for the acute treatment of manic and mixed episodes of bipolar I disorder in children and adolescents aged 10-17 years based on the positive results of one 3-week, double-blind, placebo-controlled study; the recommended dose is 2.5-10 mg BID. Although asenapine has been studied in pediatric patients with schizophrenia, it is not approved for this indication. Asenapine is not approved for pediatric use in bipolar I disorder or schizophrenia in other major markets...
November 23, 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/29165075/preferential-formulation-of-second-generation-antipsychotic-asenapine-as-inclusion-complex-with-sulphobutylether-%C3%AE-cd-captisol-in-vitro-and-in-vivo-evaluation
#14
Amelia Makarand Avachat, Juilee A Kulkarni, Charul M Avachat, Rohan Pradhan, Tushar S Suryawanshi, E M Khan, Elvis A F Martis, Evans C Coutinho, Subhash Padhye
Asenapine is an anti-psychotic agent approved by the US-FDA for treatment of acute schizophrenia and manic or bipolar I disorder in adults. It is poorly absorbed when administered orally, hence exhibits poor oral bioavailability, which limits its use in clinical practice. Consequently, enhancement in its solubility through complexation with three different cyclodextrins, viz. βCD (β cyclodextrin), HPβCD (Hydroxypropyl β cyclodextrin) and sulphobutylether-βCD (Captisol®) was attempted and compared. Kneading method was used for preparation of inclusion complexes which were characterized by FTIR, DSC, and XRD methods...
November 20, 2017: Current Drug Delivery
https://www.readbyqxmd.com/read/29126941/glycol-chitosan-functionalized-asenapine-nanostructured-lipid-carriers-for-targeted-brain-delivery-pharmacokinetic-and-teratogenic-assessment
#15
Sanjay Kumar Singh, Mahendra Kumar Hidau, Shrikant Gautam, Kiran Gupta, Krishna Pal Singh, Shio Kumar Singh, Sanjay Singh
Blood brain barrier (BBB) is a complex, tight barrier between endothelial cells of cerebral blood vessels. It acts as a physical barrier and provides access to only those moieties which are necessary for proper brain functioning. However, this selective prudence also acts as a hindrance in therapeutic targeting of brain necessitating pharmaceutical intervention. Intranasal drug delivery is one such approach which we have exploited here for targeted brain delivery of asenapine by glycol chitosan coated nanostructured lipid carrier (GC-ANLC)...
March 2018: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/29105003/anxiety-irritability-and-agitation-as-indicators-of-bipolar-mania-with-depressive-symptoms-a-post-hoc-analysis-of-two-clinical-trials
#16
Trisha Suppes, Jonas Eberhard, Ole Lemming, Allan H Young, Roger S McIntyre
BACKGROUND: Symptoms of anxiety, irritability, and agitation (AIA) are prevalent among patients with bipolar I disorder (BD-I) mania with depressive symptoms, and could potentially be used to aid physicians in the identification of this more severe form of BD-I. Using data from two clinical trials, the aims of this post hoc analysis were to describe the phenomenology of bipolar mania in terms of AIA and depressive symptoms, and to evaluate the influence of these symptoms on the likelihood of remission during treatment...
November 6, 2017: International Journal of Bipolar Disorders
https://www.readbyqxmd.com/read/29067671/a-review-of-asenapine-in-the-treatment-of-bipolar-disorder
#17
REVIEW
Eduard Vieta, José Manuel Montes
Bipolar disorder places a significant burden on the affected individuals, their family, healthcare systems and the overall economy. More treatment options are needed, especially those with better efficacy and tolerability. Asenapine is a second-generation antipsychotic approved in Europe (brand name Sycrest® ) for the treatment of moderate-to-severe manic episodes associated with bipolar I disorder in adults, and in the US (brand name Saphris® ) for the treatment of manic or mixed episodes of bipolar I disorder in adults and children aged 10-17 years...
February 2018: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29040152/acute-laryngeal-dystonia-associated-with-asenapine-use-a-case-report
#18
Nathaniel Collins, Jeffrey Sager
No abstract text is available yet for this article.
October 16, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28992737/asenapine-iloperidone-and-lurasidone-exposures-in-young-children-reported-to-u-s-poison-centers
#19
Gina Stassinos, Wendy Klein-Schwartz
CONTEXT: Asenapine, iloperidone and lurasidone are relatively new atypical antipsychotics. There is limited information on toxicity on pediatric exposures to these drugs. The objective of this study was to compare toxicity associated with asenapine, iloperidone and lurasidone exposures in young children. METHODS: A retrospective study of U.S. National Poison Data System from 2010 to 2015 of single substance exposures to asenapine, iloperidone or lurasidone in children <6 years of age that were followed to known outcome was performed...
October 10, 2017: Clinical Toxicology
https://www.readbyqxmd.com/read/28946761/randomized-double-blind-placebo-controlled-trial-of-asenapine-maintenance-therapy-in-adults-with-an-acute-manic-or-mixed-episode-associated-with-bipolar-i-disorder
#20
RANDOMIZED CONTROLLED TRIAL
Armin Szegedi, Suresh Durgam, Mary Mackle, Sung Yun Yu, Xiao Wu, Maju Mathews, Ronald P Landbloom
OBJECTIVE: The authors determined the efficacy and safety of asenapine in preventing recurrence of any mood episode in adults with bipolar I disorder. METHOD: Adults with an acute manic or mixed episode per DSM-IV-TR criteria were enrolled in this randomized, placebo-controlled trial consisting of an initial 12- to 16-week open-label period and a 26-week double-blind randomized withdrawal period. The target asenapine dosage was 10 mg b.i.d. in the open-label period but could be titrated down to 5 mg b...
January 1, 2018: American Journal of Psychiatry
keyword
keyword
80739
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"